Keisuke Takahata

Keisuke Takahata

Auto-generated profile, based on publicly available information

Keisuke Takahata

Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
SSSho Shimohama
Sho Shimohama
TTToshiki Tezuka
Toshiki Tezuka
KTKeisuke Takahata
Keisuke Takahata
SBShogyoku Bun
Shogyoku Bun
HTHajime Tabuchi
Hajime Tabuchi
DIDaisuke Ito
Daisuke Ito
Background and Objectives: Previous studies have evaluated the diagnostic effect of amyloid positron emission tomography (PET) in selected research cohorts. However, these studies did not assess the clinical impact of the combination of amyloid and tau PETs. Our objective was to evaluate the association of the combination of two PETs with changes in diagnosis, treatment, and management in a memory clinic cohort. Methods: All participants underwent amyloid [18F]florbetaben PET and tau PET using [18F]PI-2620 or [18F]Florzolotau, which are potentially useful for the diagnosis of non-Alzheimer’s disease (AD) tauopathies. Dementia specialists determined a pre- and post-PET diagnosis that existed in both a clinical syndrome (cognitive normal [CN], mild cognitive impairment [MCI], and dementia) and suspected etiology, with a confidence level. In addition, the dementia specialists determined patient treatment in terms of ancillary investigations and management. Results: Among 126 registered participants, 84.9% completed the study procedures and were included in the analysis (CN [n=40], MCI [n=25], AD [n=20], non-AD dementia [n=22]). The etiologic diagnosis changed in 25.0% in the CN, 68.0% in the MCI, and 23.8% with dementia. Overall changes in management between pre- and post-PET occurred in 5.0% of CN, 52.0% of MCI, and 38.1% of dementia. Logistic regression analysis revealed that tau PET has stronger associations with change management than amyloid PET in all participants and dementia groups. Discussion: The combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia, and the second-generation tau-PET has a strong impact on the changes in diagnosis and management in memory clinics. Classification of evidence: This study provides Class I evidence that the combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia.

16 August 2017 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
KTKeisuke Takahata
Keisuke Takahata
YKYasuyuki Kimura
Yasuyuki Kimura
CSChie Seki
Chie Seki
MTMasaki Tokunaga
Masaki Tokunaga
MIMasanori Ichise
Masanori Ichise
MHMakoto Higuchi
Makoto Higuchi
α-Amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor is a primary mediator of fast glutamatergic excitatory signaling in the brain and has been implicated in diverse neuropsychiatric diseases. We recently developed a novel positron emission tomography (PET) ligand, 2-(1-(3-([11C]methylamino)phenyl)-2-oxo-5-(pyrimidin-2-yl)-1,2-dihydropyridin-3-yl) benzonitrile ([11C]HMS011). This compound is a radiolabelled derivative of perampanel, an antiepileptic drug acting on AMPA receptors, and was demonstrated to have promising in vivo properties in the rat and monkey brains. In the current study, we performed a human PET study using [11C]HMS011 to evaluate its safety and kinetics. Four healthy male subjects underwent a 120-min PET scan after injection of [11C]HMS011. Arterial blood sampling and metabolite analysis were performed to obtain parent input functions for three of the subjects using high-performance liquid chromatography. Regional distribution volumes (V Ts) were calculated based on kinetic models with and without considering radiometabolite in the brain. The binding was also quantified using a reference tissue model with white matter as reference. Brain uptake of [11C]HMS011 was observed quickly after the injection, followed by a rapid clearance. Three hydrophilic and one lipophilic radiometabolites appeared in the plasma, with notable individual variability. The kinetics in the brain with apparent radioactivity retention suggested that the lipophilic radiometabolite could enter the brain. A dual-input graphical model, an analytical model designed in consideration of a radiometabolite entering the brain, well described the kinetics of [11C]HMS011. A reference tissue model showed small radioligand binding potential (BP*ND) values in the cortical regions (BP*ND = 0–0.15). These data suggested specific binding component of [11C]HMS011 in the brain. Kinetic analyses support some specific binding of [11C]HMS011 in the human cortex. However, this ligand may not be suitable for practical AMPA receptor PET imaging due to the small dynamic range and metabolite in the brain.

25 April 2022 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
YNYoshikazu Nakano
Yoshikazu Nakano
HSHitoshi Shimada
Hitoshi Shimada
HSHitoshi Shinotoh
Hitoshi Shinotoh
SHShigeki Hirano
Shigeki Hirano
KTKenji Tagai
Kenji Tagai
MHMakoto Higuchi
Makoto Higuchi

13 January 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
KTKeisuke Takahata
Keisuke Takahata
CSChie Seki
Chie Seki
YKYasuyuki Kimura
Yasuyuki Kimura
MKManabu Kubota
Manabu Kubota
MIMasanori Ichise
Masanori Ichise
MHMakoto Higuchi
Makoto Higuchi

1 February 2021 in NeuroImage
Verified
Journal Article
Open access
YYYasuharu Yamamoto
Yasuharu Yamamoto
KTKeisuke Takahata
Keisuke Takahata
MKManabu Kubota
Manabu Kubota
HTHarumasa Takano
Harumasa Takano
HTHiroyoshi Takeuchi
Hiroyoshi Takeuchi
MHMakoto Higuchi
Makoto Higuchi
The dopamine (DA) neurotransmission has been implicated in fundamental brain functions, exemplified by movement controls, reward-seeking, motivation, and cognition. Although dysregulation of DA neurotransmission in the striatum is known to be involved in diverse neuropsychiatric disorders, it is yet to be clarified whether components of the DA transmission, such as synthesis, receptors, and reuptake are coupled with each other to homeostatically maintain the DA neurotransmission. The purpose of this study was to investigate associations of the DA synthesis capacity with the availabilities of DA transporters and D2 receptors in the striatum of healthy subjects. First, we examined correlations between the DA synthesis capacity and DA transporter availability in the caudate and putamen using PET data with L-[β-11C]DOPA and [18F]FE-PE2I, respectively, acquired from our past dual-tracer studies. Next, we investigated relationships between the DA synthesis capacity and D2 receptor availability employing PET data with L-[β-11C]DOPA and [11C]raclopride, respectively, obtained from other previous dual-tracer assays. We found a significant positive correlation between the DA synthesis capacity and DA transporter availability in the putamen, while no significant correlations between the DA synthesis capacity and D2 receptor availability in the striatum. The intimate association of the DA synthesis rate with the presynaptic reuptake of DA indicates homeostatic maintenance of the baseline synaptic DA concentration. In contrast, the total abundance of D2 receptors, which consist of presynaptic autoreceptors and postsynaptic modulatory receptors, may not have an immediate relationship to this regulatory mechanism.

9 June 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SKShin Kurose
Shin Kurose
SMSho Moriguchi
Sho Moriguchi
MKManabu Kubota
Manabu Kubota
KTKenji Tagai
Kenji Tagai
YMYuki Momota
Yuki Momota
KTKeisuke Takahata
Keisuke Takahata
INTRODUCTION: Late‐life mood disorders (LLMDs) may represent prodromal manifestations of neurodegenerative dementia; however, the neuropathological basis of LLMDs, including depression and bipolar disorder, remains unclear. We aimed to investigate the involvement of Alzheimer's disease (AD) and non‐AD tau pathologies in LLMD participants.METHODS: Fifty‐two LLMD participants and 47 age‐ and sex‐matched healthy controls (HCs) underwent tau and amyloid beta (Aβ) positron emission tomography (PET) imaging using 18F‐florzolotau and 11C‐Pittsburgh compound B. Additionally, we conducted a clinicopathological correlation analysis in 208 autopsy cases, including various neurodegenerative diseases.RESULTS: LLMD participants were more likely to be tau PET and Aβ PET positive than HCs. The PET results were supported by the post mortem results that showed a higher likelihood of diverse tauopathies in patients with late‐life mania or depression than those without.DISCUSSION: Our PET and autopsy assays suggest that AD and diverse non‐AD tau pathologies might underlie the neuropathological basis of some LLMD cases.Highlights: Late‐life mood disorders (LLMDs) may represent prodromal states of dementia. The neuropathological basis of LLMDs remains unclear. LLMD subjects were highly likely to be tau positron emission tomography (PET) positive. Brain bank data supported our PET results. Alzheimer's disease (AD) and diverse non‐AD tau pathologies can contribute to LLMDs.